Sen. Joe Manchin seeks to block new painkiller

U.S. Sen. Joe Manchin is calling on the government's top health official to overturn the approval of a powerful painkiller, arguing that the pill Zohydro could add to the national epidemic of prescription drug abuse.

The West Virginia Democrat joins a chorus of lawmakers, state prosecutors and medical groups seeking a reversal of the Food and Drug Administration's October approval. In a letter Monday, Manchin asks Health and Human Services Secretary Kathleen Sebelius to overrule the agency's decision.

Zohydro is the first single-ingredient hydrocodone drug ever cleared for U.S. patients. The extended-release pill contains more of the narcotic pain reliever than older combination pills, such as Vicodin.

The FDA approval surprised many doctors, since the agency's own advisers voted overwhelmingly against the drug, citing its abuse potential.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Potent new painkiller stokes alarm in US

Mar 08, 2014

A potent new painkiller hit the US market this week, despite warnings from top experts that the drug may deliver a deadly setback in America's battle with opioid addiction.

US panel opposes pure hydrocodone painkiller

Dec 09, 2012

(AP)—U.S. government health experts overwhelmingly voted against a stronger version of hydrocodone on Friday, questioning the need for a new form of one of most widely abused prescription painkillers.

Recommended for you

Seaweed menace may yield new medicines

19 hours ago

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

User comments